CD38 and Miyoshi myopathy: Both mAbs efficiently directed ADCC against CD38+ cell lines, without down-modulating CD38 expression or enzymatic activity, thus representing a promising therapeutic strategy against MM and other diseases involving CD38+ cells (36).